The number of health care providers with waivers to prescribe buprenorphine for opioid use disorder increased 19% between October 2021 and September 2022 to 132,005, the Department of Health and Human Services announced today. HHS last April issued revised practice guidelines for administering buprenorphine to treat OUD, which eased requirements for clinicians to obtain a waiver to treat OUD patients with buprenorphine. According to HHS, pharmacy-filled prescriptions for the overdose reversal drug naloxone also increased 37% over the period, from a three-month average of 109,414 prescriptions in October 2021 to 150,213 in August 2022. 
 

Related News Articles

Headline
The Census Bureau reported (https://www2.census.gov/library/publications/2025/demo/acsbr-024.pdf) that the uninsured rate increased nationally to 8.2% in 2024…
Headline
The Food and Drug Administration Sept. 10 released draft guidance on non-opioid treatments for treating chronic pain and reducing prescription opioid misuse.…
Headline
A Health Affairs study published Sept. 2 found that less than 40% of Medicare beneficiaries with opioid use disorder received standard care in alignment with…
Perspective
Public
Congress returns to Washington, D.C., this week facing a long list of things to do, including several that will impact hospitals’ ability to provide access to…
Headline
The Department of Health and Human Services Sept. 4 announced new hardship exemption guidance that would allow consumers ineligible for premium tax credits or…
Headline
The Centers for Medicare & Medicaid Services Innovation Center Sept. 2 announced changes to the Achieving Healthcare Efficiency through Accountable Design…